Discounted Cash Flow (DCF) Analysis Levered
Xeris Biopharma Holdings, Inc. (XERS)
$2.57
-0.07 (-2.65%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 2.46 | 2.72 | 20.43 | 49.59 | 110.25 | 365.51 | 1,211.82 | 4,017.63 | 13,319.98 | 44,160.77 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -56.28 | -104.35 | -80.56 | -95.54 | -102.89 | -4,968.61 | -16,472.83 | -54,613.68 | -181,065.04 | -600,299.23 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -1.51 | -1.11 | -0.38 | -1.08 | -0.52 | -77.81 | -257.96 | -855.23 | -2,835.41 | -9,400.45 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -57.79 | -105.45 | -80.94 | -96.62 | -103.42 | -5,046.42 | -16,730.79 | -55,468.90 | -183,900.44 | -609,699.68 |
Weighted Average Cost Of Capital
| Share price | $ 2.57 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 135.63 |
| Cost of Debt | |
| Tax Rate | 1.48 |
| After-tax Cost of Debt | 7.63% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.696 |
| Total Debt | 198.06 |
| Total Equity | 348.57 |
| Total Capital | 546.62 |
| Debt Weighting | 36.23 |
| Equity Weighting | 63.77 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 2.46 | 2.72 | 20.43 | 49.59 | 110.25 | 365.51 | 1,211.82 | 4,017.63 | 13,319.98 | 44,160.77 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -56.28 | -104.35 | -80.56 | -95.54 | -102.89 | -4,968.61 | -16,472.83 | -54,613.68 | -181,065.04 | -600,299.23 |
| Capital Expenditure | -1.51 | -1.11 | -0.38 | -1.08 | -0.52 | -77.81 | -257.96 | -855.23 | -2,835.41 | -9,400.45 |
| Free Cash Flow | -57.79 | -105.45 | -80.94 | -96.62 | -103.42 | -5,046.42 | -16,730.79 | -55,468.90 | -183,900.44 | -609,699.68 |
| WACC | ||||||||||
| PV LFCF | -4,800.63 | -15,140.69 | -47,752.22 | -150,605.69 | -474,995.18 | |||||
| SUM PV LFCF | -693,294.40 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 5.12 |
| Free cash flow (t + 1) | -621,893.67 |
| Terminal Value | -19,932,489.55 |
| Present Value of Terminal Value | -15,528,688.70 |
Intrinsic Value
| Enterprise Value | -16,221,983.11 |
|---|---|
| Net Debt | 76.09 |
| Equity Value | -16,222,059.20 |
| Shares Outstanding | 135.63 |
| Equity Value Per Share | -119,606.37 |